blog
Last updated: 2022-04-04

Is Osimertinib Effective for Lung Cancer?

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
Is Osimertinib Effective for Lung Cancer?

Is Osimertinib Effective for Lung Cancer?

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

On June 8, 2023, Masahiro Tsuboi and colleagues from the National Cancer Center Hospital East published the results of the Phase 3 ADAURA clinical trial in "The New England Journal of Medicine." The study evaluated the efficacy and safety of adjuvant Osimertinib in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) after complete resection.

ADAURA is an international, randomized, double-blind Phase 3 trial. Patients with completely resected, EGFR mutation-positive NSCLC, regardless of prior adjuvant chemotherapy, were randomized 1:1 to either the Osimertinib group (80mg once daily for up to 3 years) or the placebo group. The primary endpoint was disease-free survival (DFS), and the secondary endpoint was overall survival (OS).

The trial included 682 participants, with 339 in the Osimertinib group and 343 in the placebo group. The 5-year OS rates for Stage II/III patients were 85% in the Osimertinib group versus 73% in the placebo group. For the overall population, the 5-year OS rates were 88% in the Osimertinib group versus 78% in the placebo group.

Based on the ADAURA trial results, Tsuboi stated that adjuvant Osimertinib significantly improved overall survival compared to placebo in patients with completely resected, EGFR mutation-positive NSCLC.

Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2304594?query=featured_home?query=featured_home

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.

Consult on LINE Contact an advisor
Fukuoka HQ: +81-92-409-5655
Formerly officially certified, No. B-066

Figure 1Figure 1

Figure 2Figure 2

Figure 3Figure 3

Figure 4Figure 4

Related Cancer Information

Related Reading

(Breast Cancer) S-1 Combined With Hormone Therapy: Is It Effective?

Kyoto University announced on January 25, 2021 that oral fluoropyrimidine S-1 combined with hormone therapy as post-operative breast cancer treatment shows promise as a new treatment option for HR+, HER2-negative primary breast cancer patients at moderate to high risk of recurrence....

2016-12-18

(Lung Cancer) Is Ivesa Effective?

ARRIVENT announced results from the FURLONG Phase III trial showing Ivesa (furmonertinib) as first-line treatment for EGFR-mutant NSCLC achieved median PFS of over 20 months, significantly outperforming first-generation EGFR inhibitors.

2022-03-18

(Solid Tumors) Is ATR Inhibitor Ceralasertib Effective?

At the ESMO 2021 Congress, Rahul Aggarwal and colleagues from UCSF presented results on the efficacy and safety of the oral ATR inhibitor Ceralasertib, both as a monotherapy and in combination with Lynparza (olaparib), in patients with ARID1A-deficient advanced solid tumors.

2015-09-21

Cancer Treatment Information

Clinical information, treatment updates, and patient resources for cancer care. Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and Ministry of Economy, Trade and Industry (B-066).

2021-09-23